|
WO2021067584A1
|
|
Methods of treatment for alpha-1 antitrypsin deficiency
|
|
WO2021041546A1
|
|
Compositions and methods for treatment of disorders associated with repetitive dna
|
|
WO2021030555A1
|
|
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
UY38837A
|
|
PROCESS OF ELABORATION OF CFTR MODULATORS
|
|
WO2021030556A1
|
|
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
US2021047323A1
|
|
Crystalline forms of cftr modulators
|
|
WO2020242935A1
|
|
Methods of treatment for cystic fibrosis
|
|
US2020361939A1
|
|
Modulators of alpha-1 antitrypsin
|
|
WO2020219867A1
|
|
Pyridone amide co-crystal compositions for the treatment of pain
|
|
WO2020214921A1
|
|
Solid forms of modulators of cftr
|
|
WO2020210640A1
|
|
Gene-editing systems for modifying a scn9a or scn10a gene and methods of use thereof
|
|
WO2020206157A1
|
|
Multicompartment macroencapsulation devices
|
|
WO2020206119A1
|
|
Process for making pyridone amides and prodrugs thereof useful as modulators of sodium channels
|
|
TW202102482A
|
|
Cystic fibrosis transmembrane conductance regulator modulating agents
|
|
WO2020176763A1
|
|
Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
|
|
WO2020146612A1
|
|
Esters and carbamates as modulators of sodium channels
|
|
WO2020146682A1
|
|
Carboxamides as modulators of sodium channels
|
|
US2020377479A1
|
|
Inhibitors of apol1 and methods of using same
|
|
WO2020118073A1
|
|
Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene
|
|
WO2020102346A1
|
|
Methods of treatment for cystic fibrosis
|
